Advertisement

All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Grants RMAT, Fast Track Designations to CB-010 in Relapsed/Refractory Non-Hodgkin Lymphoma

November 29th 2022

The FDA has granted CB-010 a regenerative medicine advanced therapy designation for relapsed/refractory large B-cell lymphoma and a fast track designation for relapsed/refractory B-cell non-Hodgkin lymphoma.

PROSPER-RCC Results May Inform Further Research on Neoadjuvant IO Approaches in RCC

November 29th 2022

Mohamad Allaf, MD, discusses innovative and unique aspects of the PROSPER-RCC trial design, areas for continued analysis within the study, and the ways in which this trial will inspire and inform continued research in renal cell carcinoma.

Nivolumab/Ipilimumab Combo Elicits 100% ORR in Checkpoint Inhibitor–Naïve Merkel Cell Carcinoma

November 29th 2022

The combination of nivolumab and ipilimumab, irrespective of the addition of stereotactic body radiation therapy, generated an overall response rate of 100% in patients with Merkel cell carcinoma who were naïve to immune checkpoint inhibitors.

Two Fox Chase Researchers Receive Grants to Pursue Innovative Kidney Cancer Research

November 29th 2022

Two Fox Chase Cancer Center researchers have received $75,000 grants from the Kidney Cancer Association to pursue studies that could improve kidney cancer treatment and care.

Roche to Withdraw US Indication for Atezolizumab in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

November 29th 2022

Roche is voluntarily withdrawing the United States indication for atezolizumab for the treatment of adults with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.

MHRA Approves Darolutamide Plus ADT and Docetaxel for Metastatic HSPC

November 29th 2022

The United Kingdom’s Medicines and Healthcare products Regulatory Agency has approved darolutamide tablets in combination with androgen deprivation therapy and docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer.

NICE Recommends Nivolumab/Chemo for HER2- Advanced Stomach and Esophageal Cancer

November 29th 2022

The United Kingdom’s National Institute for Health and Care Excellence has issued final guidance recommending the use of nivolumab plus chemotherapy as a treatment option for patients with HER2-negative advanced stomach and esophageal cancer.

Effective Communication on HPV Vaccination Benefits Is Needed

November 29th 2022

Several articles in a recent issue of the high-impact journal Science highlight areas of concern in the scientific community that may have detrimental effects on communications regarding the human papillomavirus vaccination as a cancer prevention strategy.

Cabozantinib/Atezolizumab Elicits Durable, Tolerable Clinical Activity in Advanced HNSCC

November 29th 2022

The combination of cabozantinib and atezolizumab generated rapid and durable responses in patients with advanced head and neck squamous cell carcinoma who received prior treatment with platinum-based chemotherapy.

Japan Approves Trastuzumab Deruxtecan for Previously Treated HER2+ Metastatic Breast Cancer

November 28th 2022

Japan’s Ministry of Health, Labor, and Welfare has approved trastuzumab deruxtecan for the treatment of adult patients with HER2-positive unresectable or recurrent breast cancer after prior chemotherapy, which includes trastuzumab and a taxane.

ARRY-614 Plus Immune Checkpoint Inhibition Can Induce Durable Responses in Advanced Solid Tumors

November 28th 2022

The combination of the p38 MAPK inhibitor ARRY-614 plus nivolumab with or without ipilimumab was well tolerated and elicited disease control in high-risk, PD-(L)1–refractory patients with advanced solid tumors.

Seeing Medicine Through the Eye of an Artist

November 28th 2022

For many people who go into research, there’s a moment somewhere along the way that is immediately addictive and makes you want to experience that over and over again.

ADCs Represent One of Many Improvements in GU Cancer Treatment

November 28th 2022

Daniel J. George, MD, discusses the impact that ADCs have had on the evolving treatment landscape of bladder cancer, long-term outcomes with immunotherapy in metastatic renal cell carcinoma, and highlighted current and ongoing research at the Duke Cancer Institute.

Moderate Exercise Helps Patients With CRC Live Longer By Reducing Inflammation and Improving Gut Bacteria, Including in Patients Who Are Obese

November 28th 2022

Regular physical activity can extend the lives of patients with colorectal cancer, according to a study looking at the impact of exercise on the gut microbiome of cancer patients.

FDA Issues Complete Response Letter to Poziotinib for Metastatic NSCLC Harboring HER2 Exon 20 Mutations

November 28th 2022

The FDA has issued a complete response letter to the new drug application seeking the approval of poziotinib for the treatment of patients with previously treated locally advanced or metastatic non–small cell lung cancer with HER2 exon 20 insertion mutations.

Perspectives From the Frontline: What Is Happening on the Ground With NGS Testing in NSCLC?

November 28th 2022

Benjamin P. Levy, MD; Bhuvana Ramkumar, MD; and Neil Morganstein, MD, discuss the challenges with tissue testing facing care teams, as well as multilevel hurdles in procurement, analysis of results, and insurance.

Expanding Treatment Options Elevate Outcomes for Patients With Myelofibrosis

November 28th 2022

John Mascarenhas, MD, discusses the shifts from monotherapy to combination therapies in the evolving field of myelofibrosis care.

LIVE BROADCAST: A New Targeted Therapy For Ovarian Cancer

November 28th 2022

Adjuvant Nivolumab Displays Real-world Benefits in Resected Stage IIIA Melanoma

November 27th 2022

Adjuvant nivolumab produced survival benefits in patients with resected stage IIIA melanoma, where a significant portion of patients were recurrence free at a median follow-up of over 20 months.

Extended Treatment Time With Bevacizumab Does Not Confer PFS Benefit in Ovarian Cancer

November 26th 2022

Increasing the duration of bevacizumab treatment in the frontline setting did not improve progression-free survival for patients with advanced ovarian cancer.

Advertisement
Advertisement